Document Detail

LDL = 5: Virtues and dangers of multidrug therapy of low-density lipoprotein cholesterol.
MedLine Citation:
PMID:  20377808     Owner:  NLM     Status:  MEDLINE    
Multiple-drug therapy of dyslipidemia is frequently used to achieve treatment goals in high-risk patients with coronary artery disease. The authors report a case of a patient treated with a statin, fibrate, ezetimibe, and niacin in whom a calculated low-density lipoprotein cholesterol level of 5 mg/dL was achieved.
William Phillips; Saul Schaefer
Related Documents :
14644388 - Sc-435, an ileal apical sodium co-dependent bile acid transporter (asbt) inhibitor lowe...
17563268 - Ezetimibe plus fenofibrate: a new combination therapy for the management of mixed hyper...
10591388 - An evidence-based assessment of the ncep adult treatment panel ii guidelines. national ...
20505518 - Effects of ezetimibe add-on to statin therapy on adipokine production in patients with ...
2042488 - Ultrastructural studies of rat arteriosclerosis induced by stimulation of the immune sy...
1396438 - Total cholesterol, high-density lipoprotein cholesterol, and triglycerides in children ...
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Preventive cardiology     Volume:  13     ISSN:  1751-7141     ISO Abbreviation:  Prev Cardiol     Publication Date:  2010  
Date Detail:
Created Date:  2010-04-09     Completed Date:  2010-07-16     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9813731     Medline TA:  Prev Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  69-71     Citation Subset:  IM    
Division of Cardiovascular Medicine, University of California Davis, Davis, CA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anticholesteremic Agents / adverse effects,  therapeutic use
Antilipemic Agents / adverse effects,  therapeutic use*
Azetidines / adverse effects,  therapeutic use
Cholesterol, LDL / blood,  drug effects*
Drug Therapy, Combination
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects,  therapeutic use
Hyperlipidemias / drug therapy*
Liver / drug effects
Middle Aged
Niacin / adverse effects,  therapeutic use
Procetofen / adverse effects,  therapeutic use
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Antilipemic Agents; 0/Azetidines; 0/Cholesterol, LDL; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 163222-33-1/ezetimibe; 49562-28-9/Procetofen; 59-67-6/Niacin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Quantification of the clinical modifiers impacting high-density lipoprotein cholesterol in the commu...
Next Document:  Effect of right ventricular function and pulmonary pressures on heart failure prognosis.